Latest Uk Expansion News

LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.

Alcidion has started FY27 with contracted revenue up 38% to $50.0 million, while a major UK expansion and new patient administration product widen its growth case. The company has also reaffirmed that FY27 revenue and underlying EBITDA will exceed FY26, but its capital plan now has several competing demands.

PainChek has secured a contract covering all 23 Hallmark Luxury Care Homes sites in England and Wales, adding approximately 1,800 committed resident licences to its UK base. Implementation begins in January 2027, but the agreement’s value and precise revenue contribution have not been disclosed.

Pureprofile has started FY27 with record quarterly revenue of $18.3 million and EBITDA of $2.4 million, while Platform revenue more than doubled. The ASX-listed data and insights company maintained its revenue guidance and lifted its EBITDA margin outlook to 11% to 12%.

Rua Bioscience has raised approximately NZ$1.0 million through its rights offer, well short of the NZ$2.8 million sought. The medicinal cannabis company says it still needs more working capital to fund inventory for its UK expansion.

Nick Scali delivered a sharp recovery in FY26 earnings, with net profit rising 31.2% to $75.7 million as gross margins widened and the UK loss narrowed. The furniture retailer is entering FY27 with a larger showroom network, a new distribution centre and four further ANZ openings planned.

AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.

Harvey Norman Holdings reported a 10.9% rise in profit before tax excluding one-off adjustments, driven by international retail growth and a robust property portfolio. The company declared a fully franked 13 cent final dividend, maintaining a strong balance sheet with conservative gearing.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Credit Clear Limited posted a 28% rise in FY26 revenue to $60 million, boosted by UK acquisitions and organic growth, while defending legal action by the ACCC.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

AUB Group delivered a robust FY26 with 12.2% underlying NPAT growth to $224.6 million, driven by strong international and domestic performances, and completed its strategic UK Prestige acquisition. The company declared a fully franked 71-cent final dividend and provided positive FY27 profit guidance.